Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group
▶️ Read Full Paper

📚 Source: Cephalalgia : an international journal of headache
👤 Creator: Emmanouil V Dermitz

Aim: This prospective real-world study aimed to evaluate the effectiveness of escalating eptinezumab to 300 mg in difficult-to-treat migraine patients with a partial response after two 100 mg cycles. (🧵 1/8)

50% response.

Conclusions: Escalation to eptinezumab 300 mg was associated with improved population-averaged outcomes in this selected cohort of difficult-to-treat partial responders to 100 mg, supporting, as such, dose escalation over switching therapy. (🧵 8/8)

Methods: We included adults with high-frequency episodic or chronic migraine who achieved a partial response (30% to ＜ 50% reduction in monthly headache days (MHD)) after two 100 mg eptinezumab cycles and escalated to 300 mg for two consecutive quarterly cycles. (🧵 2/8)

Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group journals.sagepub.com/doi/abs/10.1...

galcanezumab (Emgality), fremanezumab (Ajovy), and eptinezumab (Vyepti) in early pregnancy was associated with an increased risk of early pregnancy loss, a study has found.
@pharmaj.bsky.social
pharmaceutical-journal.com/article/news...
@jama.com
jamanetwork.com/journals/jam...

This article reviews the clinical and pharmacological properties of calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention and acute treatment. Monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule receptor antagonists (🧵 1/7)

Quiero estar hecha un ovillo en mi cama y no en la sala de espera del hospital de día esperando a que me llamen para el eptinezumab, Pauli 🥲

Y menos aún gritándole a la gente porque son imbéciles.

Pharmacological properties and individualized selection of CGRP inhibitors for migraine prevention and acute treatment
▶️ Read Full Paper

📚 Source: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
👤 Creator: M M Batrakhanova et al.
📅 Date: 2026-10-20

#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed

No pienso salir de casa hasta el lunes. Y porque me toca el gotero del eptinezumab.

They include monoclonal antibodies (eptinezumab, fremanezumab, galcanezumab, erenumab) and oral CGRP-receptor antagonists (atogepant, rimegepant)

Treatment Selection: Choice should consider drug availability, treatment history, patient preferences, comorbidities, and expected adherence .
🔥Preventive Migraine Medications
Anti-CGRP Pathway Drugs
*Monoclonal antibodies: erenumab, fremanezumab, galcanezumab, eptinezumab

*High: OnabotulinumtoxinA 155–195 IU intramuscular; atogepant 60 mg; *eptinezumab 100–300 mg quarterly; *fremanezumab 675 mg quarterly; galcanezumab 120 mg monthly
*Moderate: Erenumab 70–140 mg; fremanezumab 225 mg monthly

Episodic Migraine - Strong Evidence:
*High: Atogepant 60 mg oral; erenumab 70–140 mg every 4 wks subcutaneous; *fremanezumab 225 mg monthly/675 mg quarterly subcutaneous; *galcanezumab 120 mg monthly subcutaneous
*Moderate: Topiramate 100–200 mg oral; *eptinezumab 100–300 mg quarterly intravenous

Buah, a mí el fremanezumab no me daba efectos secundarios tochos, pero lo del eptinezumab es otra cosa.

Soy un cadáver ese día y el siguiente. Me duelen hasta las pestañas. Y eso sin hablar de las náuseas.

Lundbeck's Phase IV THRIVE Trial Results Show Promise for Eptinezumab in Migraine Treatment#Denmark#Lundbeck#Valby#Vyepti#Eptinezumab

Despite the established efficacy of anti-CGRP therapies-including monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and gepants (ubrogepant, rimegepant, atogepant, and zavegepant)-evidence regarding their use across critical reproductive health (🧵 3/10)

Despite the established efficacy of anti-CGRP therapies-including monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and gepants (ubrogepant, rimegepant, atogepant, and zavegepant)-evidence regarding their use across critical reproductive health (🧵 3/10)

initiated treatment with galcanezumab, erenumab, fremanezumab, or eptinezumab at specialized headache centers in Romania. Monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM were assessed at the baseline and during follow-up. (🧵 3/9)

i call upon eptinezumab! i call upon erenumab! i call upon fremanezumab! hear your servant’s prayer!!

i know that "drugs have weird names" is hack material

but for fuck's sake,

Lundbeck Celebrates Marketing Authorization for Innovative Migraine Treatment Vyepti® in Japan#Japan#Tokyo#Lundbeck#migraine_prevention#Eptinezumab

reductions in headache frequency with fremanezumab, galcanezumab, and onabotulinumtoxinA. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, erenumab, topiramate and valproate. (🧵 8/12)

more effective than placebo in reducing headache frequency. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, fremanezumab, propranolol, topiramate, and valproate. (🧵 6/12)

reductions in headache frequency with fremanezumab, galcanezumab, and onabotulinumtoxinA. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, erenumab, topiramate and valproate. (🧵 8/12)